Nuvation Bio appoints Philippe Sauvage as CFO effective October 7, 2024

Nuvation Bio Inc.

Philippe Sauvage appointed CFO; previously SVP Global Head of Operations & Access at Sanofi (2020-2024).
Initial annual base salary of $510,000; annual discretionary bonus up to 45% of base.
Option award for 750,000 shares; vests 1/4 on one-year anniversary, then monthly vesting.
Severance: 12 months base salary plus COBRA reimbursement; change-in-control double trigger with full equity acceleration.
No family relationships or material transactions with directors or officers disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Philippe Sauvage

Chief Financial Officer

NUVB · Nuvation Bio Inc.

Effective: 2024-10-07
Filed: October 7, 2024, 7:59 PM ET

Effective October 7, 2024 (the “Appointment Date”), the Board of Nuvation Bio Inc. (the “Company”) appointed Philippe Sauvage as the Company’s Chief Financial Officer and Principal Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Philippe Sauvage was appointed as Chief Financial Officer at Nuvation Bio Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective October 7, 2024 (the “Appointment Date”), the Board of Nuvation Bio Inc. (the “Company”) appointed Philippe Sauvage as the Company’s Chief Financial Officer and Principal Financial Officer.

View on SEC.gov

Nuvation Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-233794

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.